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2-BACKGROUND
•

•

•

Surgical management for EEC includes
hysterectomy, as well as lymph node (LN)
dissection, for all patients at greater-thanlow risk of LD. 1
The standard LD risk schema, defined by
Mayo Clinic, incorporates 3 risk criteria:
histologic grade, myometrial invasion (MI),
& tumor diameter (TD; Table 1).2
We recently proposed a LD risk schema
containing modified forms of risk criteria
(Table 1) that more accurately (than the
standard schema) identifies low-risk
patients who do not require LN evaluation.3

VALIDATION !!!!
•

Since this validation effort, our proposed
schema has been externally validated in a
large healthcare system in Finland.4

•

The Finnish study compared our schema
(coined “Milwaukee Model”) with a locally
developed schema and the Mayo schema.

•

Over the other schemas, the “Milwaukee
Model” showed significant improvement
in true negative rate (specificity), with a
lower expected rate of lymphadenectomy.

Table 2 – Risk Stratification of 2 Patient Cohorts by the Standard & Proposed Schemas, n (%)

Risk Level

Risk Schema & Level

Standard Risk Schema
Any TD, any grade, MI 0%
TD ≤20 mm, grade 1 or 2, MI ≤50%

Low

Proposed Risk Schema
TD ≤50 mm, any grade, MI ≤33%

TD >50 mm, any grade, MI ≤33%
LowTD >20 mm, grade 1 or 2, MI ≤50%
TD ≤50 mm, any grade, 33% < MI ≤ 66%
Intermediate
TD ≤50 mm, grade 1, MI >66%
Any TD, grade 1 or 2, 50% < MI ≤ 66%
TD >50 mm, grade 1, 33% < MI ≤ 66%
HighAny TD, grade 3, MI ≤50%
Intermediate
TD ≤50 mm, grade 2 or 3, MI >66%
Any TD, grade 1 or 2, MI >66%
TD >50 mm, any grade, MI >66%
High
Any TD, grade 3, MI >50%
TD >50 mm, grade 2 or 3, 33% < MI ≤ 66%

3-METHODS
•

Our proposed schema was retrospectively applied to a validation cohort of patients who
were geographically similar to but temporally distinct from the model development cohort.

•

Model development & validation cohorts both included patients diagnosed with stage I-III
EEC who underwent pelvic and/or para-aortic LN dissection, were non-Hispanic White or
Black, and had complete data describing grade, MI, & TD.

•

Diagnoses occurred during 2003-2013 (development cohort) & 2014-2015 (validation cohort).
Aurora Cancer Registry data were used & confirmed via chart review in Cerner/EPIC.

4-RESULTS
•

In the validation cohort, 11.7% of 247 EEC patients were LD positive or “node positive” (vs.
9.2% of 737 patients in the development cohort).

•

Risk stratification using the proposed schema produced similar true negative rates during
model development (42.8%) & validation (45.4%), both 20% higher than observed with the
standard schema (Table 2, **).

•

False negative rates were noticeably different between development & validation cohorts
using both the proposed (0% vs. 13.8%) & standard (1.47% vs. 6.90%) schemas (Table 2).
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Figure 1 – Percentage of total EEC patients who
underwent sentinel LN mapping by year during
the model development & validation periods.
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Standard Schema:
Low
Low-Intermediate
High-Intermediate
High
Proposed Schema:
Low
Low-Intermediate
High-Intermediate
High

Model Development Cohort
No LD (N=669)
LD (N=68)

Model Validation Cohort
No LD (N=218)
LD (N=29)

** 159 (23.8%) **
271 (40.5%)
99 (14.8%)
140 (20.9%)

1 (1.47%)
12 (17.6%)
14 (20.6%)
41 (60.3%)

** 56 (25.7%) **
76 (34.9%)
25 (11.5%)
61 (28.0%)

2 (6.90%)
6 (20.7%)
3 (10.3%)
18 (62.1%)

** 286 (42.8%) **
215 (32.1%)
77 (11.5%)
91 (13.6%)

0 (0%)
17 (25.0%)
14 (20.6%)
37 (54.4%)

** 99 (45.4%) **
67 (30.7%)
20 (9.17%)
32 (14.7%)

4 (13.8%)
5 (17.2%)
9 (31.0%)
11 (37.9%)

5-CONCLUSIONS
•

Application of the proposed risk stratification schema to an alternative patient cohort
verified the utility of modified risk criteria for identifying low-risk EEC patients who may
not require LN evaluation.

•

However, in the validation cohort, greater overall prevalence of LN metastasis (LD) and
low-risk classification of node-positive patients was observed.

•

Discrepancy between cohorts is likely due to greater utilization of sentinel LN mapping
during the validation period (Figures 1 & 2), allowing for increased detection of lowvolume metastases (Figure 3).5

•

Continued model development and validation may be needed to account for the increased
sensitivity of new technologies (e.g., sentinel LN mapping), as well as to test our schema in
the intraoperative setting using frozen section and in the preoperative setting using MRI.
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To assess robustness (i.e., validity) of our
proposed schema for lymphatic dissemination
(LD) risk stratification in a second cohort of
Aurora Health Care EEC patients.

Table 1 – Risk Stratification Criteria of Standard & Proposed Schemas

Number of Patients

1-OBJECTIVE
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Figure 2 – Excision of a “hot” sentinel LN
after visualization with indocyanine green &
near-infrared fluorescence imaging.

http://jnm.snmjournals.org/content/42/8/1198/F1.expansion.html

Figure 3 – (A) Regional LNs within the female pelvis & (B) Conceptualization of connectivity
between the primary tumor & nearby LNs. Sentinel LN mapping rests on the idea that tumor
cells, spreading through lymphatic channels & specific LN sequences, can be mapped using
dye or biochemical tracer injected into the uterus or cervix. When the first, or sentinel, LN in a
sequence does not stain or light up, dissemination to remaining LNs is unlikely.
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